Is lenalidomide effective in diffuse large B lymphoma?

Lenalidomide has certain therapeutic effect on diffuse largeB lymphoma. Lenalidomide is an immunomodulator that can promote the differentiation of tumor cells while inhibiting the growth and spread of tumor cells. This drug works through multiple mechanisms, including anti-angiogenesis, improving immune function, direct tumor killing, and changing the bone marrow microenvironment.

Diffuse largeBlymphoma is a highly malignantB cell non-Hodgkin lymphoma, which is commonly found in lymph nodes, spleen and other parts of the body. Lenalidomide capsules are often used to treat this disease, especially in relapsed or refractory cases, showing some efficacy.

In clinical trials, lenalidomide is often used to treat diffuse largeB cell lymphoma and has been proven to have a certain therapeutic effect. For example, in some studies, lenalidomide was used as a continuous treatment drug for patients with relapsed or refractory DLBCL, and the overall positive response rate reached 78.5 %, with the complete response rate 35.1% and the partial response rate 43.3%.

In practical applications, lenalidomide has also shown therapeutic effects on DLBCL. However, specific effects may vary based on individual differences.

Although lenalidomide has a certain therapeutic effect on diffuse largeB lymphoma, patients also need to pay attention to its possible side effects. Common side effects include thrombocytopenia, nausea, vomiting, diarrhea, etc. Therefore, patients need to take lenalidomide under the guidance of a doctor to ensure safety and effectiveness.

While taking lenalidomide, patients should regularly undergo routine blood tests, liver and kidney function tests, etc. to detect and deal with potential side effects in a timely manner. At the same time, maintaining good living and dietary habits can also help improve treatment effects and quality of life.